Login to Your Account



EB unfriends Amicus in phase III flop of Scioderm buyout candidate

By Marie Powers
News Editor

Wednesday, September 13, 2017

Amicus Therapeutics Inc. minced no words on the failure of its phase III study of SD-101 in epidermolysis bullosa (EB), the object of a potential $847 million take-out of Scioderm Inc., but John Crowley, Amicus chairman and CEO, was equally quick to defend the merits of the acquisition on a conference call Wednesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription